Three major varieties of CSPC Ouyi have been approved for production and are deemed to have been reviewed

On April 21, NMPA's official website showed that CSPC Ouyi Pharmaceutical's vortioxetine hydrobromide tablets, esomeprazole sodium for injection, and nifedipine controlled-release tablets were approved for production and deemed to have been reviewed.

.
Vortioxetine hydrobromide tablets are antidepressants, and CSPC Ouyi is the fourth domestically produced product; nifedipine controlled-release tablets are long-acting antihypertensive drugs, which are planned to be included in the seventh batch of centralized procurement
.
Vortioxetine is a novel antidepressant with a multi-target mechanism of action developed by Lundbeck Pharma.
-HT3 receptor antagonism
.
The product was approved for marketing in the United States in 2013 and in China in November 2017.
It is currently not included in the National Medical Insurance Catalogue, and the market is in its infancy
.
According to data from Minet.
com, in 2020, the sales of vortioxetine in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as Chinese public medical institutions) and the terminal terminal of Chinese urban physical pharmacies exceeded 85 million yuan
.
In Chinese urban physical pharmacy terminals, vortioxetine sales rose as high as 241%
.
Up to now, there are 4 local companies in the domestic market that have production approvals for vortioxetine hydrobromide tablets, including Chia Tai Tianqing, Bite Pharmaceutical, Kanghong Pharmaceutical and CSPC Ouyi
.
Esomeprazole is a new generation of proton pump inhibitor for injection, which is clinically used for the treatment of gastroesophageal reflux disease, erosive reflux esophagitis,
etc.
With the approval of CSPC Ouyi's product, 21 companies have over-reviewed esomeprazole sodium for injection
.
According to data from Minet.
com, the domestic market of esomeprazole injection has continued to expand in recent years, with terminal sales of over 3.
3 billion yuan in Chinese public medical institutions in 2020
; Nifedipine is a dihydropyridine calcium antagonist developed by Bayer, which selectively inhibits the transmembrane transport of calcium ions into cardiomyocytes and smooth muscle cells, and inhibits the release of calcium ions from intracellular pools without changing plasma calcium ions.
concentration, clinically used to treat hypertension and angina pectoris
.
According to data from Minet.
com, in 2020, the sales of terminal nifedipine in China's public medical institutions exceeded 6 billion yuan.
In the first half of 2021, its sales exceeded 4 billion yuan, a year-on-year increase of 25.
46%
.
It is worth mentioning that the nifedipine sustained-release and controlled-release dosage form is the seventh batch of varieties to be collected, and there are currently 8 companies that have over-evaluated the sustained-release dosage form
.
Data source: Minet database, NMPA Note: Minet China's urban physical pharmacy terminal competition pattern database is an enlarged version of continuous monitoring of all categories covering physical pharmacies in 297 cities and above across the country (excluding county and rural physical pharmacies).
A database of urban brick-and-mortar pharmacies
.
The above sales are calculated based on the average retail price of the product in the terminal
.